Skip to main content

Table 2 NVC alterations in the SSc cohort (n = 44)

From: Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement

 

Giant capillaries

Neoangiogenesis

Avascular areas

Density

Females vs males

3.0 (1–19) vs 6.0 (3–9)

2.5 (0–10) vs 4.2 (0–8)

1.5 (0–10) vs 1.1 (0–3)

6.2 (2.3–14.5) vs 6.9 (5.9–7.9)

Diffuse vs limited

3.0 (1–11) vs 3.1 (1–19)

1.0 (0–8) vs 2.7 (0–10)

2.0 (0–10) vs 1.2 (0–9)

5.2 (2.3–14.5) vs 6.5 (3.0–12)

Anti-Scl70 vs ACA

1.8 (1–11) vs 3.4 (1–19)

2.8 (0–8) vs 2.7 (0–10)

1.8 (0–10) vs 1.5 (0–9)

4.9 (2.3–8.8) vs 6.1 (2.4–14.5)

Anti-Scl70 vs others

1.8 (1–11) vs 8.7 (1–19)

2.8 (0–8) vs 1.4 (0–10)

1.8 (0–10) vs 0.5 (0–2)

4.9 (2.3–8.8) vs 7.5 (4.0–14.5)

ACA vs others

3.4 (1–19) vs 8.7 (1–19)

2.7 (0–10) vs 1.4 (0–10)

1.5 (0–10) vs 0.5 (0–2)

6.1 (2.3–14.5) vs 7.5 (4.0–14.5)

No ulcers vs ulcers

3.2 (1–18) vs 3.0 (1–19)

2.7 (0–8) vs 2.0 (0–10)

1.5 (0–10) vs 1.4 (0–5)

6.1 (2.3–14.5) vs 5.9 (4.0–9.8)

No GE vs GE

5.7 (1–17) vs 2.8 (1–19)

1.6 (0–3) vs 3.0 (0–10)

1.0 (0–4) vs 1.5 (0–10)

6.9 (3.0–9.4) vs 6.0 (2.3–14.5)

sPAP < 45 mmHg vs > 45 mmHg

3.3 (1–19) vs 2.0 (1–3)

2.4 (0–10) vs 6.5 (0–8)

1.2 (0–9) vs 4.3 (2–10)*

6.3 (2.4–14.5) vs 5.2 (2.3–5.9)

DLCO < 50 % vs > 50 %

2.5 (1–7) vs 4.1 (1–19)

5.0 (0–8) vs 2.7 (0–10)

1.5 (0–4) vs 1.2 (0–10)

5.3 (4.6–14.5) vs 6.1 (2.3–12)

FVC < 80 % vs > 80 %

3.4 (1–19) vs 3.0 (2–9)

2.7 (0–10) vs 2.4 (0–8)

0.9 (0–9) vs 2.1 (0–10)

6.5 (2.3–14.5) vs 5.3 (2.3–7.9)

No honeycombing vs honeycombing

3.6 (1–19) vs 2.3 (1–3)

1.5 (0–10) vs 5.0 (1–6)

0.7 (0–4) vs 1.2 (0–10)

6.3 (4.0–9.9) vs 5.0 (2.3–14.5)

Skin score < 14 vs > 14

3.0 (1–19) vs 8.0 (1–11)

2.7 (0–10) vs 1.2 (0–8)

1.4 (0–9) vs 1.8 (0–10)

6.6 (2.4–12.0) vs 4.6 (2.3–14.5)

No iloprost vs iloprost

3.6 (1–19) vs 3.0 (1–16)

2.0 (0–8) vs 3.0 (0–10)

0.7 (0–3.4) vs 1.5 (0–10)*

6.1 (4.0–9.9) vs 6.1 (2.3–14.5)

No bosentan vs bosentan

3.4 (1–19) vs 2.0 (1–6)

1.8 (0–10) vs 5.8 (3–8)*

0.9 (0–10) vs 1.8 (2–4)

6.3 (2.3–14.5) vs 5.6 (5.0–8.8)

Early pattern vs others

0.5 (1–4) vs 3.3 (1–19)*

3.1 (1–10) vs 2.2 (0–10)

0.5 (0–1) vs 1.5 (0–10)*

9.5 (9.0–10.8) vs 5.9 (2.3–14.5)*

Active pattern vs others

8.0 (1–19) vs 1.6 (1–8)*

2.0 (0–10) vs 3.0 (0–10)

0.7 (0–3) vs 2.0 (0–10)*

6.9 (4.0–14.5) vs 5.3 (2.3–12.0)

Late pattern vs others

2.1 (1–7) vs 6.3 (1–19)*

2.7 (0–8) vs 2.4 (0–10)

2.1 (1–10) vs 0.5 (0–3)*

5.0 (2.3–9.8) vs 7.5 (4.0–14.5)*

VEGF-A <0.8U vs >0.8U

3.0 (1–19) vs 3.8 (1–9)

2.0 (0–10) vs 4.5 (0–6)

1.5 (0–10) vs 1.5 (0–3)

6.4 (2.3–12.0) vs 4.7 (4.0–14.5)

CSURI >2.94 vs <2.94

3.0 (1–19) vs 3.1 (1–11)

1.8 (0–8) vs 2.6 (0–10)

1.5 (0–10) vs 0.3 (0–1)*

5.8 (2.3–14.5) vs 8.3 (4.0–12.0)*

  1. ACA anti-centromere, anti-Scl70 anti-topoisomerase I, DLCO carbon monoxide diffusing capacity, FVC forced vital capacity, GE gastro-esophageal, NVC nailfold videocapillaroscopy, sPAP systolic pulmonary artery pressure on echocardiography, SSc systemic sclerosis, vs versus
  2. * p < 0.05
Back to article page